India based Jubilant Biosys, subsidiary of Jubilant Life Sciences, and Germany based Sanofi Deutschland have announced a strategic alliance to discover and develop small molecule inhibitors for multiple targets in the metabolic disorders therapeutic area.
The research alliance is aimed at developing therapeutic small molecules that will address the unmet needs in diabetes and obesity.
As per the terms of the agreement, Jubilant shall provide Sanofi integrated drug discovery and early development services across computational, synthetic chemistry, biology, GLP/ GMP services, to identify lead candidates and demonstrate clinical proof of mechanism in the metabolic disorders therapeutic areas. The research for the projects, which has been initiated, will be undertaken primarily at state-of-the-art R&D labs of Jubilant Biosys (Bengaluru, India) and Jubilant Chemsys (Noida, India).
Dr Sriram Rajagopal, chief scientific officer, Jubilant Biosys said, "We are excited to partner with Sanofi, one of the global healthcare leader, to offer our integrated drug discovery solutions. Over the past few years, we have been strengthening our therapeutic area expertise in the scientific perspective and this collaboration is a validation of our efforts. This alliance demonstrates Jubilant's commitment to global innovation and we look forward to a long mutually beneficial partnership."
Dr Philip Just Larsen, vice president, Global Head of Diabetes Research & Translational Medicine, Sanofi Deutschland said, "The collaboration with Jubilant underscores our commitment to engaging innovators around the world, as we develop the next generation of improved therapies for people with diabetes."
